Abstracts Archive - Page 1163 of 2607 - ACR Meeting Abstracts

Abstract Number: 404 • 2019 ACR/ARP Annual Meeting
Autoantibody Profiles Delineate Three Distinct Subsets of Scleromyositis
Julie D'Aoust¹, Valérie Leclair ², Geneviève Gyger ³, Alain Meyer ⁴, Marvin Fritzler ⁵, Océane Landon-Cardinal ⁶, Erin O'Ferrall ⁷, Jason Karamchandani ⁷, Benjamin Ellezam ⁸, Rami Massie ⁷, Minoru Satoh ⁹, Yves Troyanov ¹⁰ and Marie Hudson ¹¹, ¹McGill University, Montreal, QC, Canada, ²Division of Rheumatology, Department of Medicine, Jewish General Hospital; Clinical Epidemiology Unit, Department of Medicine, Karolinska Institutet, Montreal, QC, Canada, ³Division of Rheumatology, Department of Medicine, Jewish General Hospital, Montreal, QC, Canada, ⁴Centre de Reference des Maladies Autoimmunes Rares, Hôpitaux Universitaires de Strasbourg, Strasbourg, France, ⁵Cumming School of Medicine, University of Calgary, Calgary, AB, Canada, ⁶Division of Rheumatology, Centre hospitalier de l'Université de Montréal; Department of Medicine, Université de Montréal, Montreal, QC, Canada, ⁷Montreal Neurological Institute, Montreal, QC, Canada, ⁸Centre hospitalier universitaire Sainte-Justine, Montreal, QC, Canada, ⁹Department of Clinical Nursing, School of Health Sciences, University of Occupational and Environmental Health, Kitakyushu, Japan, ¹⁰Division of Rheumatology, Department of Medicine, Hôpital du Sacre-Coeur de Montreal, Montreal, QC, Canada, ¹¹Jewish General Hospital, Lady Davis Institute for Medical Research, and Department of Medicine, McGill University, Montreal, QC, Canada
Background/Purpose: Myopathy is an important cause of morbidity in systemic sclerosis (SSc). Nevertheless, scleromyositis remains incompletely characterized owing at least in part to its clinical…
Abstract Number: 405 • 2019 ACR/ARP Annual Meeting
Anti-MDA5 Dermatomyositis: A Case Series, Systematic Review and Meta-analysis of the Literature
Mohammad Ryadh Pokeerbux¹, Luc Dauchet ², Benjamin Lopez ³, Hélène Maillard ¹, Sandrine Morell-Dubois ¹, Eric Auxenfants ⁴ and Eric Hachulla ⁵, ¹Department of Internal Medicine and Clinical Immunology, CHU Lille, University of Lille, Lille, France, ²Department of Epidemiology, CHU Lille, University of Lille, Lille, France, ³Institute of Immunology, CHU Lille, University of Lille, Lille, France, ⁴Department of Internal Medicine, Roubaix Hospital, Roubaix, France, ⁵Dept. of Internal Medicine and Clinical Immunology, Hôpital Claude Huriez, University of Lille, Lille, France, Lille, France
Background/Purpose: Anti-MDA5 dermatomyositis is characterized by little or no muscle involvement, distinct cutaneous features and an increased risk of severe interstitial lung disease (ILD) with…
Abstract Number: 406 • 2019 ACR/ARP Annual Meeting
Myositis Related Antibodies and Interstitial Lung Disease: Variables Associated with Baseline Lung Function and Functional Improvement: Results from a Multicentric Latin-american Cohort
VERONICA WOLFF¹, MARIA LAURA ALBERTI ², FELIPE REYES ³, ERNESTO JUAREZ ⁴, JORGE ROJAS-SERRANO ⁴, FABIAN CARO ², IVETTE BUENDIA ⁴, MAYRA MEJIA ⁴, MATIAS FLORENZANO ⁵ and FRANCISCO PAULIN ², ¹INSTITUTO NACIONAL DEL TORAX - UNIVERSIDAD DE CHILE, SANTIAGO, Chile, ²HOSPITAL MARIA FERRER, BUENOS AIRES, Argentina, ³HOSPITAL CLINICO UNIVERSIDAD DE CHILE, SANTIAGO, Chile, ⁴INSTITUTO NACIONAL DE ENFERMEDADES RESPIRATORIAS DE MEXICO DF, CIUDAD DE MEXICO, Mexico, ⁵INSTITUTO NACIONAL DEL TORAX, SANTIAGO, Chile
Background/Purpose: Idiopathic inflammatory myopathies (IIM) comprise a group of autoimmune diseases associated to different myositis related antibodies (MRA), that determine distinct phenotypes but share some…
Abstract Number: 407 • 2019 ACR/ARP Annual Meeting
Utility of Anti-SSA/SSB Assay and Anti-Ro 52 Antibody Assay in Routine Clinical Practice for Risk Assessment of Patients with Idiopathic Inflammatory Myositis
Galina Marder ¹, Sonali Narain², Maria-Louise Barilla-Labarca ¹ and Ana Valle ¹, ¹Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Hempstead, NY, ²Northwell Health, Great Neck, Long Island, NY
Background/Purpose: Idiopathic inflammatory myopathies (IIM) are chronic autoimmune diseases affecting multiple organ systems and associated with a diverse autoantibody profile. Anti-SSA/SSB are the most frequent…
Abstract Number: 408 • 2019 ACR/ARP Annual Meeting
Frequency of Concomitant Non-aminoacyl-transfer-RNA Synthetase Autoantibodies in Patients with Antisynthetase Syndrome
Alexis Katz¹, Soumya Chatterjee ² and Yuxuan Jin ³, ¹Cleveland Clinic, Cleveland, OH, ²Cleveland Clinic, Cleveland, ³Quantitative Health Science, Cleveland Clinic, Cleveland, OH
Background/Purpose: Antisynthetase syndrome (ASSD) is an autoimmune disease with features including interstitial lung disease (ILD), myositis, inflammatory arthritis, Raynaud phenomenon, and mechanic’s hands.¹ Eight aminoacyl-transfer-RNA…
Abstract Number: 409 • 2019 ACR/ARP Annual Meeting
Antisynthetase Syndromes: Correlation of Indirect Immunofluorescence Patterns with Diagnosis Criteria Fulfillment
Martín Greco¹, María Jesús García De Yébenes ², Inmaculada Alarcón ³, Iñigo Rua Figueroa ⁴, Estíbaliz Loza ², Carlos Rodriguez-Lozano ⁵, Anahy Brandy-Garcia ⁶ and Loreto Carmona ², ¹Rheumatology Department. Hospital Universitario de Gran Canaria Dr. Negrín., Las Palmas, Spain, ²Instituto de Salud Musculoesquelética - Inmusc., Madrid, Spain, ³Biochemical Department, Autoimmunity Laboratory. Hospital Universitario de Gran Canaria Dr. Negrín., Las Palmas, Canarias, Spain, ⁴Hospital Doctor Negrin, Las Palmas, ⁵Rheumatology Department. Hospital Universitario de Gran Canaria Dr. Negrín., Madrid, Spain, ⁶Hospital Universitari Germans Trias i Pujol, Badalona, Spain
Background/Purpose: The antisynthetase syndromes (ASSD) are characterized by the presence of anti-aminoacyl transfer RNA synthetase (ARS) autoantibodies and a clinical classic triad of myositis, arthritis,…
Abstract Number: 410 • 2019 ACR/ARP Annual Meeting
Prevalence of Malignancy in Myositis Patients with Anti-aminoacyl-tRNA Synthetase Antibodies: A Single Center Retrospective Study and Literature Review
Taiga Kuga¹, Yoshiyuki Abe ², Kurisu Tada ³, Masakazu Matsushita ¹, Ken Yamaji ¹ and Naoto Tamura ¹, ¹Department of Internal Medicine and Rheumatology, Juntendo University School of Medicine, Tokyo, Japan, ²Department of Rheumatology, Juntendo University, Tokyo, Japan, Tokyo, Japan, ³Juntendo University School of Medicine, Tokyo, Japan
Background/Purpose: Anti-aminoacyl-tRNA synthetase antibodies (anti-ARS antibodies) are related to Idiopathic Inflammatory Myopathy (IIM) and Anti-Synthetase Syndrome (ASS). While anti-TIF1-γ antibody and anti-NXP-2 antibody are highly…
Abstract Number: 411 • 2019 ACR/ARP Annual Meeting
Frequency and Staining Patterns of Antinuclear Antibodies in Myositis Patients Without Known Myositis-specific Autoantibodies
Maria casal-Dominguez¹, Iago Pinal-Fernandez ¹, Ana Marin ², Maria Teresa Sanz-Martinez ², Andres Baucells-de la Pena ³, Katherine Pak ⁴, Yuji Hosono ¹, Lisa Christopher-Stine ⁵ and Andrew L Mammen ⁴, ¹NIH, Bethesda, ²Vall d'Hebron Hospital, Barcelona, Spain, ³Hospital de la Santa Creu i Sant Pau, Barcelona, Spain, ⁴National Institutes of Health, Bethesda, ⁵Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: Objective:To determine the frequency and staining patterns of antinuclear antibodies (ANA) in myositis patients who do not have known myositis-specific autoantibodies.Methods: Material and methods:Sera…
Abstract Number: 412 • 2019 ACR/ARP Annual Meeting
Elevated Serum BAFF Levels in Patients with Dermatomyositis: Association with Interstitial Lung Disease
Takashi Matsushita¹, Tadahiro Kobayashi ¹, Miyu Kano ¹, Yasuhito Hamaguchi ¹ and Kazuhiko Takehara ², ¹Kanazawa University, Kanazawa, Japan, ²Department of Dermatology, Kanazawa University, Kanazawa, Japan
Background/Purpose: Patients with dermatomyositis (DM) frequently have myositis-specific autoantibodies (MSAs), which are closely associated with different clinical features. Patients with anti-aminoacyl-tRNA synthetase (ARS) antibody (Ab)…
Abstract Number: 413 • 2019 ACR/ARP Annual Meeting
Performance of the Patient Reported Outcomes Measurement Information System 29-item Profile in Comparison to the Clinical Disease Activity Index (CDAI) and Routine Assessment of Patient Index Data 3 (RAPID3) in an Australian Rheumatoid Arthritis Cohort
Kathryn Gibson¹, Dana Gerogevsky ², Frank Huang ³, Ray Fang ³ and Joseph Descallar ⁴, ¹Liverpool Hospital, Sydney, New South Wales, Australia, ²Royal Prince Alfred Hospital, Sydney, Australia, ³University of New South Wales, Sydney, New South Wales, Australia, ⁴Ingham Research Institute, Sydney, New South Wales, Australia
Background/Purpose: The Patient-Reported Outcomes Measurement Information System (PROMIS) was developed to improve measurement of patient-reported outcomes. A large study from the US reported guarded support…
Abstract Number: 414 • 2019 ACR/ARP Annual Meeting
Treat-to-Target Approach in the Management of Elderly Rheumatoid Arthritis Patients
Vivek Joseph ¹, Swetha Vontela ², Surjeet Dheer³, Molly Weinberg ⁴, Zuhayr Haq ² and Arundathi Jayatilleke ⁵, ¹Drexel University, PHILADELPHIA, PA, ²Drexel University, Philadelphia, ³Mercy Catholic Medical Center, Philadelphia, ⁴Drexel University, Philadlephia, ⁵Drexel, Philadelphia, PA
Background/Purpose: With the advent of biologic therapy for RA, the American College of Rheumatology advocates a treat to target (TTT) approach in the treatment of…
Abstract Number: 415 • 2019 ACR/ARP Annual Meeting
Validation of a Satisfaction Measure for Use in Total Joint Replacement Clinical Trials
Susan Goodman¹, Bella Mehta ², Cynthia Kahlenberg ³, Jackie Finik ⁴, Mark Figgie ⁵, Michael Parks ², Douglas Padgett ³, Vinicius Antao ³, Adolf Yates ⁶, Bryan Springer ⁷, Stephen Lyman ³ and Jasvinder Singh ⁸, ¹Hospital For Special Surgery/Weill Cornell Medicine, New York, NY, ²Hospital for Special Surgery/Weill Cornell Medicine, New York, ³Hospital for Special Surgery, New York, ⁴Hospital for Special Surgery, New York, NY, New York, NY, ⁵Hospital for Special Surgery/Weill Cornell Medicine, New York, NY, New York, NY, ⁶University of Pittsburgh School of Medicine Shadyside, Pittsburgh, ⁷OrthoCarolina Hip and Knee Center, Charlotte, ⁸University of Alabama Medical Center, Birmingham
Background/Purpose: Patient satisfaction after total hip (THR) and total knee replacement (TKR) is a core outcome selected by the Outcomes Measurement in Rheumatology (OMERACT), yet…
Abstract Number: 416 • 2019 ACR/ARP Annual Meeting
Global Management of Patients with Knee Osteoarthritis Begins with Quality of Life Assessment: A Systematic Review
Josep Verges¹, Marianna Vitaloni ¹, Rosa Sciortino ², Maritza Quintero ², Marco Bibas ¹, Jordi Monfort ³, Francisco de Abajo ⁴, Marco Matucci-Cerinic ⁵, Patrick du Souich ⁶, Ingrid Möller ⁷, Guy Eakin ⁸ and Angie Botto-van Bemden ⁸, ¹Osteoarthritis International Foundation, Barcelona, Spain, ²De los Andes University, Merida, Venezuela, ³Hospital del Mar, Barcelona, Spain, ⁴Universidad de Alcalá, Madrid, Spain, ⁵University of Florence, Department of Medicine, Florence, Italy, Florence, Italy, ⁶University of Montreal, Montreal, Canada, ⁷Poal Institute, Barcelona, Spain, ⁸Arthritis Foundation, Atlanta
Background/Purpose: Knee OA (KOA) associates with remarkable functional restrictions due to pain that seriously affect social and emotional well-being, reducing the quality of life (QoL).…
Abstract Number: 417 • 2019 ACR/ARP Annual Meeting
Contribution of Pain Relief to Function, Fatigue, and Quality of Life When Inflammation Is Controlled in Patients with Rheumatoid Arthritis
Mart A.F.J. van de Laar¹, Janet Pope ², Yvonne Lee ³, Bruno Fautrel ⁴, Kei Ikeda ⁵, Amanda Quebe ⁶, Xiang Zhang ⁶, Carol Gaich ⁶, Francesco De Leonardis ⁶, Jeffrey Lisse ⁶, Jennifer Workman ⁶, Roy Fleischmann ⁷, Mark Genovese ⁸ and Peter Taylor ⁹, ¹Arthritis Center Twente, Enschede, Netherlands, ²Western University, London, ON, Canada, ³Northwestern University Feinberg School of Medicine, Chicago, ⁴Pitié-Salpêtrière Hospital, Department of Rheumatology, AP-HP, Sorbonne University, UPMC university, Paris, Ile-de-France, France, ⁵Chiba University Hospital, Chiba, Japan, ⁶Eli Lilly and Company, Indianapolis, IN, ⁷Metroplex Clinical Research Center and University of Texas Southwestern Medical Center, Dallas, TX, ⁸Stanford University, Stanford, CA, ⁹University of Oxford, Oxford, United Kingdom
Background/Purpose: Baricitinib, an oral selective Janus kinase 1 and 2 inhibitor, has shown clinical efficacy and patient-reported pain relief in patients (pts) with RA and…
Abstract Number: 418 • 2019 ACR/ARP Annual Meeting
Work Productivity Is Associated with Disease Activity and Functional Ability in Chinese Patients with Axial Spondyloarthritis Using a Smart-Phone Management System: A Prospective Cohort Study
Xiaofei Liu ¹, Yanyan Wang ², Wenji Chen ¹, Shiyan Mo ³, Xiaojian Ji ⁴ and Feng Huang², ¹Department of Rheumatology,Hainan Hospital of PLA General Hospital,, sanya, Hainan, China (People's Republic), ²Department of Rheumatology, Chinese PLA General Hospital, beijing, China (People's Republic), ³Department of Rheumatology,Hainan Hospital of PLA General Hospital,, sanya, ⁴Department of Rheumatology, Chinese PLA GeneralHospital,, Beijing, Beijing, China (People's Republic)
Background/Purpose: Axial spondyloarthritis (axSpA) usually affects young people and may lead to work disability(WD). We used the "Smart-phone SpondyloArthritis Management System”, an interactive mobile health…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].